labetuzumab

Home
Ligands
labetuzumab

GtoPdb Ligand ID: 8251

Synonyms: CEACIDE® | hMN14

Comment: Labetuzumab is a humanised mouse monoclonal antibody targeting CEACAM5 (CD66e), a tumour marker that can be measured in serum.
Labetuzumab can be labelled with radioactive isotopes such as yttrium-90 and iodine-131, providing targeted radioimmumotherapy.
Labetuzumab has been used to generate an antibody-drug conjugate (ADC) called labetuzumab govitecan, in which the antibody is covalently bound to SN-38, the active metabolite of the topoisomerase inhibitor, irinotecan.

Summary
Biological activity
Clinical data
References

References
1. Hansen HJ, Armour KL. (2004) CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies. Patent number: US6676924. Assignee: Immunomedics, Inc.. Priority date: 22/02/1994. Publication date: 13/01/2004.

References

1. Hansen HJ, Armour KL. (2004)
CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies.
Patent number: US6676924. Assignee: Immunomedics, Inc.. Priority date: 22/02/1994. Publication date: 13/01/2004.